5.76
                                            
            Lyra Therapeutics Inc stock is traded at $5.76, with a volume of 13,640.
            It is up +6.70% in the last 24 hours and down -9.75% over the past month.
            Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
        
        See More
    Previous Close:
              $5.52
            Open:
              $5.53
            24h Volume:
                13,640
            Relative Volume:
              0.51
            Market Cap:
                $9.47M
            Revenue:
              $770.00K
            Net Income/Loss:
              $-38.84M
            P/E Ratio:
              -0.4055
            EPS:
                -14.2049
            Net Cash Flow:
                $-43.02M
            1W Performance:
              -7.53%
            1M Performance:
              -9.75%
            6M Performance:
                -0.84%
            1Y Performance:
              -57.15%
            Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
                  
                      Lyra Therapeutics Inc
                    
                Sector
                  Industry
                  Phone
                  
                      617-373-4600
                    
                Address
                  
                      480 ARSENAL WAY, WATERTOWN, MA
                    
                Compare LYRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                LYRA
                            
                             Lyra Therapeutics Inc | 5.76 | 9.08M | 770.00K | -38.84M | -43.02M | -14.20 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| May-07-24 | Downgrade | BofA Securities | Buy → Underperform | 
| May-07-24 | Downgrade | H.C. Wainwright | Buy → Neutral | 
| May-07-24 | Downgrade | Jefferies | Buy → Hold | 
| May-06-24 | Downgrade | William Blair | Outperform → Mkt Perform | 
| Oct-06-23 | Resumed | BTIG Research | Buy | 
| Aug-31-23 | Initiated | H.C. Wainwright | Buy | 
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight | 
| May-26-20 | Initiated | BTIG Research | Buy | 
| May-26-20 | Initiated | BofA/Merrill | Buy | 
| May-26-20 | Initiated | Jefferies | Buy | 
| May-26-20 | Initiated | William Blair | Outperform | 
                    View All
                     
                  
                Lyra Therapeutics Inc Stock (LYRA) Latest News
Will Lyra Therapeutics Inc. stock see insider buyingTrade Signal Summary & Expert Approved Momentum Trade Ideas - newser.com
Risk adjusted return profile for Lyra Therapeutics Inc. analyzedWeekly Market Outlook & High Accuracy Buy Signal Tips - newser.com
Is Lyra Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Gains Summary & AI Optimized Trading Strategy Guides - newser.com
How Lyra Therapeutics Inc. stock benefits from global expansionJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Is Lyra Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Stock Summary & Daily Technical Stock Forecast Reports - newser.com
Identifying reversal signals in Lyra Therapeutics Inc.July 2025 Retail & Advanced Technical Signal Analysis - newser.com
What indicators show strength in Lyra Therapeutics Inc.Weekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Is Lyra Therapeutics Inc. still worth holding after the dipRate Hike & Low Drawdown Investment Strategies - newser.com
Why Lyra Therapeutics Inc. stock could see breakout soonGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
Will Lyra Therapeutics Inc. outperform the market2025 Year in Review & Proven Capital Preservation Tips - newser.com
Can a trend reversal in Lyra Therapeutics Inc. lead to recoveryJuly 2025 WrapUp & AI Enhanced Trading Alerts - newser.com
Price momentum metrics for Lyra Therapeutics Inc. explainedJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Is Lyra Therapeutics Inc. stock a bargain at current levelsFed Meeting & Daily Risk Controlled Trade Plans - newser.com
Published on: 2025-10-29 21:52:23 - newser.com
What valuation multiples suggest for Lyra Therapeutics Inc. stockInsider Selling & Technical Entry and Exit Tips - newser.com
Will earnings trigger a reversal in Lyra Therapeutics Inc.2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
Order flow analysis tools used on Lyra Therapeutics Inc.Portfolio Value Report & Risk Adjusted Swing Trade Ideas - newser.com
How Lyra Therapeutics Inc. stock responds to policy changesPortfolio Performance Summary & Daily Stock Trend Watchlist - Fundação Cultural do Pará
Aug Selloffs: Is Lyra Therapeutics Inc. stock a bargain at current levelsJuly 2025 Volume & AI Driven Stock Price Forecasts - Fundação Cultural do Pará
How buybacks impact Lyra Therapeutics Inc. stock valuePortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Published on: 2025-10-27 05:33:04 - newser.com
Lyra Therapeutics Stock Fell 11% in a Week, What Now? - Trefis
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lyra Therapeutics Inc Stock (LYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | 
|---|---|---|---|---|---|---|---|
| Palasis Maria | President & CEO | Jul 10 '25 | Sale | 8.91 | 1,565 | 13,944 | 1,098,435 | 
| Cavalier Jason | Chief Financial Officer | Jul 10 '25 | Sale | 8.91 | 684 | 6,094 | 519,316 | 
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):
                 
            
         
                     
                             Get the Stockscreener App
                    Get the Stockscreener App